House legislation proposes early warning system for drug shortages

Thompson, Cheryl A.
August 2011
American Journal of Health-System Pharmacy;8/1/2011, Vol. 68 Issue 15, p1379
Academic Journal
The article reports an early warning system proposed by the House Legislation for drug shortages, and mentions that if this bipartisan bill is enacted it will improve patient safety by reducing shortages in life-saving medications. It refers to the Preserving Access to Life-Saving Medications Act of 2011, in which the House legislation is longer than the similarly titled Senate bill. Also presented is a table of pending federal legislation on drug shortages.


Related Articles

  • Support grows for pharmacist provider status bill.  // Chain Drug Review;4/18/2016, Vol. 38 Issue 7, p67 

    The article discusses the enactment of the Ensuring Seniors Access to Local Pharmacies Act of 2015 for the pharmaceutical sector in the U.S.

  • A win for drug data-mining: Vermont law restricting marketing overturned. Conn, Joseph // Modern Healthcare;11/29/2010, Vol. 40 Issue 48, p13 

    The article reports that a three-judge panel in the 2nd U.S. Circuit Court of Appeals overturned a Vermont law seeking to restrict the use of prescription drug data in the marketing of pharmaceuticals to physicians.

  • The Case for Pediatric Exclusivity. Milne, Christopher // Pharmaceutical Technology;Sep2011, Vol. 35 Issue 9, p38 

    In this article the author comments the reauthorization of pediatric exclusivity provisions in the U.S. He notes that reauthorization of the pediatric exclusivity, which requested pharmaceutical industry to conduct pediatric studies in exchange of additional market protection under the Food and...

  • A Critique of the European Commission's Sector Inquiry into the Pharmaceutical Sector. Rosenberg, David // Antitrust Magazine;Spring2010, Vol. 24 Issue 2, p35 

    The article comments on the process and conclusions of the Pharma Inquiry into the European pharmaceutical sector conducted by the European Commission in January 2008. Commenting on the evidence collecting phase of the inquiry, the author states that the Commission, acting through the...

  • Bigger Role. Bigger Target. Agres, Ted // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p8 

    The article discusses the bigger role of the Food and Drug Administration (FDA) in the reauthorization of the Prescription Drug User Fee Act (PDUFA) in the U.S. It notes the five major provisions to be considered in the final bill in which FDA's new responsibilities and authorities for oversight...

  • AHA urges Senate committee to address the record number of drug shortages in the nation's hospitals.  // AHA News;8/8/2011, Vol. 47 Issue 16, p7 

    The article reports on calls by the American Hospital Association (AHA) for the U.S. legislators to use the reauthorization of the "Prescription Drug User Free Act" (PDUFA) that will help boost the country's drug supply. It points out that the reauthorization presents an opportunity to make some...

  • FDA agrees to deal that speeds reviews. Arnold, Matthew // McKnight's Long-Term Care News;Oct2011, Vol. 32 Issue 10, p31 

    The article reports on the agreement between the U.S. Food and Drug Administration and the biopharmaceutical industry that the Prescription Drug User Fee Act, which requires drug firms to provide about two-thirds of the amount spent by the agency on drug reviews, should be revamped.

  • FDA Struggles with Risk Management and Drug Safety. Wechsler, Jill // Pharmaceutical Technology;Sep2010, Vol. 34 Issue 9, p26 

    The article reports on the move of U.S. Food and Drug Administration (FDA) to provide advantages and disadvantages of establishing Risk Evaluation and Mitigation Strategies (REMS) programs in pharmaceutical industry. The agency proposed some ways on how to prevent opioid misuse and abuse...

  • Feds to pharma: Fraud cases are in our crosshairs. KALTWASSER, JARED // njbiz;11/8/2010, Vol. 23 Issue 45, p5 

    The article considers the measures taken by pharmaceutical companies in the U.S. to comply with the regulations enforced by the Food and Drug Administration (FDA). According to Jack Garvey, principal at Compliance Architects, the pharmaceutical industry has changed from being vertically...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics